Chronic prostatitis/chronic pelvic pain syndrome: Role of alpha blocker therapy

Urologia Internationalis

Volumn 78, Issue 2, 2007, Pages 97-105

  Lee, Shaun Wen Huey ^a   Liong, Men Long ^a   Yuen, Kah Hay ^a   Liong, Yee Vonne ^a   Krieger, John N ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; DOXAZOSIN; EFLORNITHINE; LABETALOL; NAFTOPIDIL; PHENOXYBENZAMINE; PHENTOLAMINE; PLACEBO; TAMSULOSIN; TERAZOSIN;

BLADDER NECK STENOSIS; CHRONIC PROSTATITIS; CLINICAL TRIAL; DRUG DOSE ESCALATION; HUMAN; LOWER URINARY TRACT SYMPTOM; MICTURITION DISORDER; NOSE DISEASE; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RETROGRADE EJACULATION; REVIEW; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URETHRA; UROGENITAL TRACT DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; MALE; PROSTATITIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33846896416     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098064     Document Type: Review

References (62)

1. Lee S, Cheah P, Liong M, Yuen K, Schaeffer A, Propert K, Krieger J, Northern Malaysia Prostatitis Study Group CPCRN: Demographic and clinical characteristics of chronic prostatitis: prospective comparison of the University of Sciences Malaysia Cohort with the United States National Institutes of Health Cohort. J Urol 2007;177:153-157 .
2. Schaeffer AJ, Landis JR, Knauss JS, Propert KJ, Alexander RB, Litwin MS, Nickel JC, O'Leary MP, Nadler RB, Pontari MA, Shoskes DA, Zeitlin SI, Fowler JE Jr, Mazurick CA, Kishel L, Kusek JW, Nyberg LM; Chronic Prostatitis Collaborative Research Network Group: Demographic and clinical characteristics of men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. J Urol 2002;168:593-598.
3. Ku JH, Paick JS, Kim SW: Chronic prostatitis in Korea: a nationwide postal survey of practicing urologists in 2004. Asian J Androl 2005;7:427-432.
4. Krieger JN, Nyberg L Jr, Nickel JC: NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-237.
5. Drach GW: Prostatitis and prostatodynia: their relationship to benign prostatic hypertrophy. Urol Clin North Am 1980;7:79-88.
6. Buck AC: Disorders of micturition in bacterial prostatitis. Proc R Soc Med 1975;68:508-511.
7. Nickel JC: The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr Opin Urol 2006;16:5-10.
8. 1 adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia. Urology 2003;62:34-41.
9. 1 adrenoceptors. Eur Urol 1999;36:2-6.
10. Terzic A, Puceat M, Vassort G, Vogel SM: Cardiac alpha-1 adrenoceptors: an overview. Pharmacol Rev 1993;45:147-175.
11. 1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int 2000;85(Suppl 2):6-11.
12. 1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001; 88(Suppl 2):27-34.
13. Theodorou C, Konidaris D, Moutzouris G, Becopoulos T: The urodynamic profile of prostatodynia. BJU Int 1999;84:461-463.
14. Turner-Warwick R, Whiteside CG, Worth PH, Milroy EJ, Bates CP: A urodynamic view of the clinical problems associated with bladder neck dysfunction and its treatment by endoscopic incision and trans-trigonal posterior prostatectomy. Br J Urol 1973;45:44-59.
15. Arnold T: Urodynamic significance of minor urological problems in the male. Urol Clin North Am 1979;6:193-197.
16. Murnaghan GF, Millard RJ: Urodynamic evaluation of bladder neck obstruction in chronic prostatitis. Br J Urol 1984;56:713-716.
17. Kaplan SA, Te AE, Jacobs BZ: Urodynamic evidence of vesical neck obstruction in men with misdiagnosed chronic nonbacterial prostatitis and the therapeutic role of endoscopic incision of the bladder neck. J Urol 1994;152:2063-2065.
18. Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Tojo M, Ito H: The nature of detrusor bladder neck dyssynergia in non-neurogenic bladder dysfunction. J Auton Nerv Syst 1997;66:163-168.
19. Kaplan SA, Santarosa RP, D'Alisera PM, Fay BJ, Ikeguchi EF, Hendricks J, Klein L, Te AE: Pseudodyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic nonbacterial prostatitis and the role of biofeedback as a therapeutic option. J Urol 1997;157:2234-2237.
20. Toh KL, Ng CK: Urodynamic studies in the evaluation of young men presenting with lower urinary tract symptoms. Int J Urol 2006;13:520-523.
21. Gonzalez RR, Te AE: Is there a role for urodynamics in chronic nonbacterial prostatitis? Curr Urol Rep 2006;7:335-338.
22. Hruz P, Danuser H, Studer UE, Hochreiter WW: Non-inflammatory chronic pelvic pain syndrome can be caused by bladder neck hypertrophy. Eur Urol 2003;44:106-110.
23. Barbalias GA, Meares EM Jr, Sant GR: Prostatodynia: clinical and urodynamic characteristics. J Urol 1983;130:514-517.
24. Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE: Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol 1982;54:729-731.
25. Hellstrom WJ, Schmidt RA, Lue TF, Tanagho EA: Neuromuscular dysfunction in nonbacterial prostatitis. Urology 1987; 30: 183-188.
26. Doble A, Walker MM, Harris JR, Taylor-Robinson D, Witherow RO: Intraprostatic antibody deposition in chronic abacterial prostatitis. Br J Urol 1990;65:598-605.
27. Barbalias GA: Prostatodynia or painful male urethral syndrome? Urology 1990;36:146-153.
28. Webster GD, Lockhart JL, Older RA: The evaluation of bladder neck dysfunction. J Urol 1980;123:196-198.
29. Norlen LJ, Blaivas JG: Unsuspected proximal urethral obstruction in young and middle-aged men. J Urol 1986;135:972-976.
30. Graversen PH, Gasser TC, Wasson JH, Hinman F Jr, Bruskewitz RC: Controversies about indications for transurethral resection of the prostate. J Urol 1989;141:475-481.
31. Lopatin WB, Martynik M, Hickey DP, Vivas C, Hakala TR: Retrograde transurethral balloon dilation of prostate: innovative management of abacterial chronic prostatitis and prostatodynia. Urology 1990;36:508-510.
32. Mayo ME, Ross SO, Krieger JN: Few patients with 'chronic prostatitis' have significant bladder outlet obstruction. Urology 1998;52:417-421.
33. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, Yap HW, Krieger JN: Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo-controlled trial. J Urol 2003;169:592-596.
34. Mehik A, Hellström P, Lukkarinen O, Sarpola A, Alfthan O: Prostatic tissue pressure measurement as a possible diagnostic procedure in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome. Urol Res 2000;28:316-318.
35. Caine M, Raz S: Some clinical implications of adrenergic receptors in the urinary tract. Arch Surg 1975;110:247-250.
36. Osborn DE, George NJ, Rao PN, Barnard RJ, Reading C, Marklow C, Blacklock NJ: Prostatodynia - physiological characteristics and rational management with muscle relaxants. Br J Urol 1981;53:621-623.
37. Dunzendorfer U: alpha-Difluoromethylornithine (alpha DFMO) and phenoxybenzamine hydrochloride in the treatment of chronic non-suppurative prostatitis. Arzneimittelforschung 1981;31:382-385.
38. Te AE: A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions. Clin Ther 2002;24:851-861.
39. Kaneko S, Minami K, Yachiku S, Kurita T: Bladder neck dysfunction: the effect of the alpha-adrenergic blocking agent phentolamine on bladder neck dysfunction and a fluorescent histochemical study of bladder neck smooth muscle. Invest Urol 1980;18:212-218.
40. Neal DE Jr, Moon TD: Use of terazosin in prostatodynia and validation of a symptom score questionnaire. Urology 1994;43:460-465.
41. Barbalias GA, Nikiforidis G, Liatsikos EN: Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol 1998;159:883-887.
42. Drabick JJ, Gambel JM, Mackey JF: Prostatodynia in United Nations peacekeeping forces in Haiti. Mil Med 1997;162:380-383.
43. de la Rosette JJ, Karthaus HF, van Kerrebroeck PE, de Boo T, Debruyne FM: Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha-1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. Eur Urol 1992;22:222-227.
44. Gul O, Eroglu M, Ozok U: Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. Int Urol Nephrol 2001;32:433-436.
45. Lacquaniti S, Destito A, Servello C, Candidi MO, Weir JM, Brisinda G, Alcini E: Terazosine and tamsulosin in non-bacterial prostatitis: a randomized placebo-controlled study. Arch Ital Urol Androl 1999;71:283-285.
46. Evliyaoglu Y, Burgut R: Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin versus placebo. Int Urol Nephrol 2002;34:351-356.
47. Shoskes DA, Hakim L, Ghoniem G, Jackson CL: Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. J Urol 2003;169:1406-1410.
48. Ruggieri MR Sr, Braverman AS, Pontari MA: Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 2005;174:1743-1748.
49. Nickel JC: The three As of chronic prostatitis therapy: antibiotics, alpha-blockers and anti-inflammatories. What is the evidence? BJU Int 2004;94:1230-1233.
50. Propert KJ, Alexander RB, Nickel JC, Kusek JW, Litwin MS, Landis JR, Nyberg LM, Schaeffer AJ: Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology 2002;59:870-876.
51. Nickel JC, Narayan P, McKay J, Doyle C: Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double-blind trial. J Urol 2004;171:1594-1597.
52. Dimitrakov JD, Kaplan SA, Kroenke K, Jackson JL, Freeman MR: Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach. Urology 2006;67:881-888.
53. Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O'Leary MP, Pontari MA, McNaughton-Collins M, Shoskes DA, Comiter CV, Datta NS, Fowler JE Jr, Nadler RB, Zeitlin SI, Knauss JS, Wang Y, Kusek JW, Nyberg LM Jr, Litwin MS: Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004;141:581-589.
54. Mehik A, Alas P, Nickel JC, Sarpola A, Helström PJ: Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology 2003;62:425-429.
55. Pontari MA; Network NCPCR: Comparison of alfuzosin therapy for alpha-blocker-naive patients with chronic prostatitis/chronic pelvic pain syndrome, in progress.
56. McNeill SA, Hargreave TB, Geffriaud-Ricouard C, Santoni J, Roehrborn CG: Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. Urology 2001;57:459-465.
57. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, Yap HW, Krieger JN: Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology 2004;64:881-886.
58. 1-adrenoceptors. Consensus update. Pharmacol Rev 1995;47:267-270.
59. 1-antagonist selective for the lower urinary tract: in vitro studies. Neurourol Urodyn 1994;13:473-474.
60. 1-adrenoceptors. Jpn J Pharmacol 1999;79:447-503.
61. van Kerrebroeck P: The efficacy and safety of a new once-a-day formulation of an alpha-blocker. Eur Urol 2001;39:19-26.
62. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:54-58.